On October 27, Mindray (300760) released its third quarterly report. The report showed that in the first three quarters of 2022, Mindray achieved revenue of CNY 23.3 billion, an increase of 20.1% year-on-year, and recorded net profit of CNY 8.1 billion, an increase of 21.6% year-on-year.

Hologic reported after the close of the market on Monday that a continued decline in sales of COVID-19 assays and ongoing difficulties securing semiconductor chips contributed to an overall 28 percent year-over-year decline in its fiscal fourth quarter revenues.

DiaSorin reported Thursday its third quarter revenues declined 5 percent year over year with waning COVID-19 testing demand, despite rising revenues across its other diagnostics businesses.

Danaher on Thursday reported a 6 percent year-over-year increase in third quarter revenues as its subsidiaries see shifting demand for COVID-19-related products, such as diagnostic tests and pharmaceuticals.

The company raised its earnings forecast for 2022 on estimates of $7.8 billion in annual sales related to COVID-19 testing.

Roche’s third-quarter results have revealed a clear sign that the bumper sales boosting companies that have provided products to diagnose, treat or prevent COVID-19 since the start of the pandemic are starting to tail off.

Canadian diagnostics firm MedMira said on Friday that its Vyra COVID-19 Antigen Test has been CE marked and is now available in countries that accept the designation.

The US Food and Drug Administration said Friday it has granted Emergency Use Authorization for Abbott's real-time PCR monkeypox test, the Alinity m MPXV assay.

The US Food and Drug Administration said on Tuesday that it is updating its policy on Emergency Use Authorizations for COVID-19 tests and limiting its review of new submissions.

US Food and Drug Administration officials said Wednesday that over-the-counter molecular assays could bridge gaps in monkeypox testing, as agency officials also continued work on creating guidance specific to antigen tests for the disease.